Table 3.

Kidney outcomes of SLE patients with aPLN. Values are mean ± SD, median (IQR), or n (%) unless otherwise specified.

Variables	Non-RASI, n = 17	RASI, n = 40	HR (95% CI)	p
Followup, mos	48 ± 34; 36 (12–119)	93 ± 48; 90 (12–166)		< 0.001
Kidney disease progression
ESKD or 15% eGFR decline	5 (29)	6 (15)	0.23 (0.06–0.87)^a	0.030^a
ESKD or 30% eGFR decline	4 (24)	3 (8)	0.11 (0.02–0.59)^a	0.010^a
ESKD or 50% eGFR decline	3 (18)	3 (8)	0.05 (0.00–0.54)^a	0.014^a
Blood pressure control	15 (88)	29 (73)	0.91 (0.48–1.75)^b	0.778^b
Proteinuria control
< 3.5 g/d	17 (100)	39 (98)	0.66 (0.36–1.2)^c	0.187^c
< 1.0 g/d	15 (88)	35 (88)	0.76 (0.41–1.41)^c	0.759^c
< 0.5 g/d	9 (53)	29 (73)	1.24 (0.57–2.73)^c	0.587^c

Data in bold face are statistically significant.
↵a HR and p values are adjusted for baseline MAP and its interaction with eGFR.
↵b HR and p values are adjusted for baseline MAP.
↵c HR and p values are adjusted for baseline proteinuria. SLE: systemic lupus erythematosus; aPLN: antiphospholipid-associated nephropathy; IQR: interquartile range; RASI: renin-angiotensin system inhibitor; ESKD: endstage kidney disease; eGFR: estimated glomerular filtration rate.